Prospects for prevention and treatment of vascular cognitive impairment.
With the aging population and rising prevalence of vascular disease in developed and developing countries, increasing numbers of individuals are at risk of cognitive impairment. Despite the potential of the therapeutics that are currently under investigation, none have yet fulfilled their promise for the prevention and treatment of dementia. The term vascular cognitive impairment (VCI) describes individuals with significant cognitive impairment arising from vascular disease. Risk factors predisposing to stroke correlate with brain changes, cognitive loss and Alzheimer's disease pathology. The volume of the infarcts and white matter changes, silent lacunar infarcts, and global and regional brain atrophy may be imaged non-invasively, targeted as surrogates of the dementia processes and considered parameters to be targeted for interventional strategies. As the greatest chance to prevent cognitive impairment and its progression is by intervening in the early stages or prior to any change, the development of preventative therapeutics is an important strategy. Non-invasive magnetic resonance imaging techniques may help to identify a subgroup of patients in whom infarct prevention, via risk factor control, may be of paramount importance. As the pathophysiology of dementia becomes more fully understood by coupling neuropsychological with neuroimaging, genetic and pathological features, there is the potential for the establishment of diagnostic criteria of the early phase of VCI and the testing of novel interventional strategies.
Department of Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, 339 Windermere Road, N6A 5A5 London, Ontario, Canada. sdilegge@uwo.ca
Silvia
S
Di Legge
Vladimir
V
Hachinski
D000375:Aging / Q000473:pathology; D001921:Brain / Q000473:pathology; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D012307:Risk Factors; D014652:Vascular Diseases / Q000150:complications / Q000188:drug therapy
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors